BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31005440)

  • 1. Changing Patterns of Anticoagulation After Total Hip Arthroplasty in the United States: Frequency of Deep Vein Thrombosis, Pulmonary Embolism, and Complications With Rivaroxaban and Warfarin.
    Glassberg MB; Lachiewicz PF
    J Arthroplasty; 2019 Aug; 34(8):1793-1801. PubMed ID: 31005440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty.
    Bawa H; Weick JW; Dirschl DR; Luu HH
    J Am Acad Orthop Surg; 2018 Oct; 26(19):698-705. PubMed ID: 30153117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Obesity Associated With Increased Risk of Deep Vein Thrombosis or Pulmonary Embolism After Hip and Knee Arthroplasty? A Large Database Study.
    Sloan M; Sheth N; Lee GC
    Clin Orthop Relat Res; 2019 Mar; 477(3):523-532. PubMed ID: 30624321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: A systematic review and meta-analysis.
    Liu J; Zhao J; Yan Y; Su J
    Medicine (Baltimore); 2019 Mar; 98(9):e14539. PubMed ID: 30817570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMS reimbursement reform and the incidence of hospital-acquired pulmonary embolism or deep vein thrombosis.
    Gidwani R; Bhattacharya J
    J Gen Intern Med; 2015 May; 30(5):588-96. PubMed ID: 25519222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for Venous Thromboembolic Prophylaxis Following Total Hip and Total Knee Arthroplasty: An Analysis of Safety and Efficacy Accounting for Surgeon Selection Bias.
    Heckmann ND; Piple AS; Wang JC; Richardson MK; Mayfield CK; Oakes DA; Christ AB; Lieberman JR
    J Arthroplasty; 2023 Jul; 38(7 Suppl 2):S412-S419.e1. PubMed ID: 36870517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
    Freedman KB; Brookenthal KR; Fitzgerald RH; Williams S; Lonner JH
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):929-38. PubMed ID: 10901307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge.
    Laliberté F; Coleman CI; Bookhart B; Schein J; Martin S; Wynant W; Xiao Y; Lefebvre P; Kaatz S
    Curr Med Res Opin; 2018 Nov; 34(11):1967-1974. PubMed ID: 29749269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are Revision Hip Arthroplasty Patients at Higher Risk for Venous Thromboembolic Events Than Primary Hip Arthroplasty Patients?
    Courtney PM; Boniello AJ; Levine BR; Sheth NP; Paprosky WG
    J Arthroplasty; 2017 Dec; 32(12):3752-3756. PubMed ID: 28807468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
    Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
    J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracranial Hemorrhage in Deep Vein Thrombosis/Pulmonary Embolus Patients Without Atrial Fibrillation.
    Lamsam L; Sussman ES; Iyer AK; Bhambhvani HP; Han SS; Skirboll S; Ratliff JK
    Stroke; 2018 Aug; 49(8):1866-1871. PubMed ID: 29991654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty.
    Deirmengian GK; Heller S; Smith EB; Maltenfort M; Chen AF; Parvizi J
    J Arthroplasty; 2016 Oct; 31(10):2237-40. PubMed ID: 27118182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
    Runner RP; Gottschalk MB; Staley CA; Pour AE; Roberson JR
    J Arthroplasty; 2019 Apr; 34(4):729-734. PubMed ID: 30685257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
    Kalani C; Awudi E; Alexander T; Udeani G; Surani S
    Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty.
    Piple AS; Wang JC; Kang HP; Mills ES; Mayfield CK; Lieberman JR; Christ AB; Heckmann ND
    J Arthroplasty; 2023 Aug; 38(8):1613-1620.e4. PubMed ID: 36805121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
    Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
    Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
    J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.